Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00842556
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00839683
- Locations
- 🇺🇸
Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT00831779
- Locations
- 🇺🇸
Temple University General Clinical Research Center, Philadelphia, Pennsylvania, United States
🇺🇸Va San Diego Healthcare System, San Diego, California, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 497
- Registration Number
- NCT00736879
- Locations
- 🇺🇸
Valley Research, Fresno, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Endocrine Research Solutions, Inc., Roswell, Georgia, United States
Renal Mechanism of Action/Splay vs. TmG
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1
- Registration Number
- NCT00726505
- Locations
- 🇺🇸
University Of Texas Health Center At San Antonio, San Antonio, Texas, United States
Effects of Single Oral Dose Dapagliflozin QT Study
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00688493
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Add-on to Thiazolidinedione (TZD) Failures
- Conditions
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 972
- Registration Number
- NCT00683878
- Locations
- 🇺🇸
Diabetes Research Center, Tustin, California, United States
🇺🇸Endocrine Research Associates, Jackson, Mississippi, United States
🇺🇸Dallas Diabetes & Endocrine Center, Dallas, Texas, United States
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00680745
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1240
- Registration Number
- NCT00673231
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 631
- Registration Number
- NCT00663260
- Locations
- 🇺🇸
Marin Endocrine Care & Research, Inc., Greenbrae, California, United States
🇺🇸Diabetes Medical Center Of California, Northridge, California, United States
🇺🇸Office Of Richard Cherlin, Md, Los Gatos, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.